A Phase 1 interventional study of Tislelizumab and Pamiparib in Solid Tumors, sponsored by BeiGene. Completed at 29 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-06.
Sponsored by BeiGene · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This trial studied the safety, pharmacokinetics, and antitumor activity of the anti-programmed cell death 1 (PD-1) monoclonal antibody (mAb) BGB-A317 (tislelizumab) in combination with the poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor BGB-290 (pamiparib) in participants with advanced solid tumors.
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Participants who had the below specified confirmed that had progressed to the advanced or stage:
Arm 1: Participants with , platinum-sensitive high-grade epithelial, non-mucinous, ovarian cancer, fallopian tube, or primary peritoneal cancer (EOC) must have met the following criteria:
i. Must have had at least 2 prior platinum-containing treatments in any treatment setting.
ii. Must have had platinum-sensitive recurrent disease and must not have progressed (by [RECIST] v1.1 criteria) within 6 months of the completion of the last platinum-containing .
iii. Arm 1a: Participants with relapsed, platinum-sensitive high-grade EOC with either known deleterious or suspected deleterious germline or somatic breast cancer susceptibility gene 1/2 (BRCA1/2) mutations or with homologous recombination deficiency (HRD).
iv. Arm 1b: Participants with relapsed, platinum-sensitive high grade EOC who otherwise met the above criteria and were without known germline or somatic BRCA1/2 mutations and without HRD mutation.
Arm 2: Participants with triple negative breast cancer must have met the following criteria:
i. 0-1 prior platinum-containing treatment in any treatment setting.
ii. Participants who received at least 1 prior treatment but not more than 3 prior lines of treatment in the advanced or metastatic setting.
iii. Known deleterious or suspected deleterious germline or somatic BRCA1/2 mutations or with documented HRD.
Arm 3: Participants with metastatic castration-resistant prostate cancer, including but not limited to mutations in homologous recombination (HR) pathways and/or defined by HRD algorithms, and must have met the following criteria:
i. May be either chemotherapy-naïve, but must have received prior abiraterone acetate and/or enzalutamide treatment, or have previously had no more than 2 taxane-based chemotherapy lines of treatment, including docetaxel and carbazitaxel. If docetaxel was used more than once, this was considered as 1 line of treatment.
ii. At least 2 weeks since the completion of prior flutamide, bicalutamide, and nilutimide, or enzalutamide and abiraterone treatment.
iii. Documented prostate cancer with one of the following:
iv. Known deleterious or suspected deleterious germline or somatic BRCA1/2 mutations or with documented HRD.
Arm 4: Participants with extensive-stage disease SCLC must have met the following criteria:
i. Received at least 1 and not more than 2 prior lines of treatment; ii. At least 1 prior line of treatment must have contained a platinum agent
Arm 5: Participants with human epidermal growth factor receptor-2 ()-negative gastric or gastroesophageal junction cancer must have met the following criteria:
i. May have received at least 1 and not more than 2 prior lines of treatment
Arm 6: Participants with locally advanced or metastatic urothelial (muscle-invasive bladder, ureter, urethra, or renal pelvis) cancer must have met the following criteria:
i. Received at least 1 and not more than 2 prior lines of treatment in the advanced or metastatic disease setting; ii. At least 1 prior line of treatment must have contained a platinum agent
Arm 7: Participants with advanced or metastatic pancreatic adenocarcinoma must have met the following criteria:
i. Received at least 1 but not more than 2 lines of treatment in either an advanced or metastatic setting; ii. At least 1 prior treatment for advanced or metastatic disease must have contained a platinum agent; iii. Participants with known deleterious germline or somatic BRCA1/2 mutation could be considered for the study even if platinum naïve.
Arm 8: (Note: Closed to enrollment) Participants with advanced or metastatic recurrent non-ovarian gynecological cancers (endometrial cancer, cancer of the cervix and participants with tumors known to be mismatch repair deficient or HRD positive) must have met the following criteria:
i. Participants with a complete response, partial response, or stable disease from at least 1 prior platinum-containing treatment in any treatment setting; ii. The Sponsor medical monitor would approve tumor types for Arm 8 prior to screening.
Key Exclusion Criteria:
Symptomatic or . Note: Baseline magnetic resonance imaging of the brain and spinal cord was required for SCLC participants enrolled in Arm 4 if they had a history of CNS disease.
Note: Participants with previously treated CNS metastatic disease were eligible for any arm if CNS metastatic disease was asymptomatic, clinically stable, and did not require or anticonvulsants within a minimum of 4 weeks of enrollment.
Active diseases or history of autoimmune diseases that may have relapsed.
Note: Participants with the following diseases were not excluded and may have proceeded to further screening:
Any condition that required systemic treatment with either corticosteroids (> 10 mg daily of prednisone or equivalent) or other medication within 2 weeks of the study drug administration.
Note: Participants who were currently or had previously been on any of the following steroid regimens were not excluded:
Any of the following cardiovascular criteria:
Note: Other protocol-defined Inclusion/Exclusion criteria may have applied.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received tislelizumab and pamiparib (dose escalation) until determination of the maximum tolerated dose/recommended Phase 2 dose.
Biological: Tislelizumab · Drug: Pamiparib
Participants received tislelizumab and pamiparib (dose expansion).
Biological: Tislelizumab · Drug: Pamiparib
Also known as: BGB-A317
Also known as: BGB-290
Part A: Number Of Participants Experiencing Adverse Events (AEs)
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. All AEs reported are treatment-emergent, which was defined as having a reported onset time or worsening in severity on or after the date of the first dose of study treatment through 30 days after the last dose (permanent discontinuation of study treatment) or initiation of new anticancer therapy. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
Time frame: From Day 1 up to 4 years and 7 months
Part A: Number Of Participants Experiencing Dose-limiting Toxicity (DLT)
DLT was defined as an AE or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications, and occurs during the first 21 days following the first dose of tislelizumab and pamiparib in Cycle 1 and meets protocol-specified criteria. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
Time frame: 21 days following the first dose of tislelizumab and pamiparib in Cycle 1
Part B: Objective Response Rate (ORR)
ORR was defined as the percentage of participants with a best overall response of complete response (CR) and partial response (PR).
Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)
Part B: Progression-free Survival (PFS)
PFS was defined as the time from first dose of study medication to the first documented objective disease progression or death due to any cause, whichever occurred first.
Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)
Part B: Duration Of Response (DOR)
DOR, defined as the time from the first determination of an objective response, was assessed by investigator per Response Evaluation Criteria in Solid Tumors v1.1 until the first documentation of progression or death, whichever occurred first. Results are reported only for arms with responders.
Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)
Part B: Disease Control Rate (DCR)
DCR was defined as the percentage of participants with a best overall response of CR, PR, and stable disease (SD).
Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)
Part B: Clinical Benefit Rate (CBR)
CBR was defined as the percentage of participants with a best overall response of CR, PR, and SD lasting ≥ 24 weeks.
Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)
Part B: Overall Survival (OS)
OS was defined as the time from the date of first dose of study drug to death due to any cause.
Time frame: From Day 1 Every 3 months following completion or discontinuation of the treatment (up to 4 years and 7 months)
Part A: Minimum Observed Plasma Concentration (Ctrough) Of Tislelizumab
Time frame: Cycle 4 Day 1 (0 hours and 4 hours) post dose
Part A: Ctrough Of Pamiparib
Time frame: Cycle 2 Day 1 (Pre-dose and 7 hours Post-dose)
Part A: Maximum Observed Plasma Concentration At Steady State (Cmax,ss) Of Pamiparib
Time frame: Cycle 2 Day 1 (Pre-dose and 7 hours Post-dose)
Part A: Time To Reach Maximum Plasma Concentration At Steady State (Tmax,ss) Of Pamiparib
Time frame: Cycle 2 Day 1 (Pre-dose and 7 hours Post-dose)
Part A: Ctrough At Steady State (Ctrough,ss) Of Pamiparib
Time frame: Cycle 2 Day 1 (Pre-dose and 7 hours Post-dose)
Part A: ORR
ORR was defined as the percentage of participants with a best overall response of CR and PR.
Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)
Part A: PFS
PFS was defined as the time from first dose of study medication to the first documented objective disease progression or death due to any cause, whichever occurred first.
Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)
Part A: DCR
DCR was defined as the percentage of participants with a best overall response of CR, PR, and SD.
Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)
Part A: CBR
CBR was defined as the percentage of participants with a best overall response of CR, PR, and SD lasting ≥ 24 weeks.
Time frame: Starting from Day 1 until disease progression (up to 4 years and 7 months)
Part A: OS
OS was defined as the time from the date of first dose of study drug to death due to any cause.
Time frame: Starting from Day 1 Every 3 months following completion or discontinuation of the treatment (up to 4 years and 7 months)
Part A: Percentage Of Participants With Anti-drug Antibodies (ADAs) For Tislelizumab
Immunogenicity was summarized by participants who were ADA positive and developed detectable ADAs.
Time frame: Within 24 hours before the start of the first dose of tislelizumab in Cycle 1, Day 8 of Cycle 1, and Day 1 of Cycle 2, Cycle 3, Cycle 4, Cycle 5, Cycle 9, and Cycle 17
Part B: Number Of Participants Experiencing AEs
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. All AEs reported are treatment-emergent, which was defined as having a reported onset time or worsening in severity on or after the date of the first dose of study treatment through 30 days after the last dose (permanent discontinuation of study treatment) or initiation of new anticancer therapy. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
Time frame: Day 1 of Cycle 1 up to 4 years and 7 months
Part B: Ctrough Of Tislelizumab
As pre-specified in the protocol, pharmacokinetic evaluations were performed for all Part B dose expansion arms combined.
Time frame: Cycle 4 Day 1 ( 0 hours and 4 hours post dose)
Part B: Maximum Observed Plasma Concentration (Cmax) Of Tislelizumab
As pre-specified in the protocol, pharmacokinetic evaluations were performed for all Part B dose expansion arms combined.
Time frame: Cycle 4 Day 1 ( 0 hours and 4 hours) post dose
Part B: Ctrough Of Pamiparib
As pre-specified in the protocol, pharmacokinetic evaluations were performed for all Part B dose expansion arms combined.
Time frame: Cycle 2 Day 1 (7 hours Post-dose)
Part B: Cmax Of Pamiparib
As pre-specified in the protocol, pharmacokinetic evaluations were performed for all Part B dose expansion arms combined.
Time frame: Cycle 2 (7 hours Post-dose)
Part B: Percentage Of Participants With ADAs For Tislelizumab
Immunogenicity was summarized by participants who developed detectable ADAs. Treatment-emergent ADAs: sum of both treatment-induced ADAs and treatment-boosted ADAs.
Time frame: 24 hours predose of Day 1 of every cycle
Part A: A total of 49 participants with advanced solid tumors were enrolled in Part A of the study (dose escalation phase) at a total of 5 sites or community oncology centers in Australia. Part B: A total of 180 participants with advanced solid tumors were enrolled in Part B of the study (dose expansion phase).
| Milestone | Part A: Dose Escalation Phase - Cohort 1 | Part A: Dose Escalation Phase - Cohort 2 | Part A: Dose Escalation Phase - Cohort 3 | Part A: Dose Escalation Phase - Cohort 4 | Part A: Dose Escalation Phase - Cohort 5 | Part B: Dose Expansion Phase - Arm 1a | Part B: Dose Expansion Phase - Arm 1b | Part B: Dose Expansion Phase - Arm 2 | Part B: Dose Expansion Phase - Arm 3 | Part B: Dose Expansion Phase - Arm 4 | Part B: Dose Expansion Phase - Arm 5 | Part B: Dose Expansion Phase - Arm 6 | Part B: Dose Expansion Phase - Arm 7 | Part B: Dose Expansion Phase - Arm 8 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 12 | 12 | 6 | 13 | 6 | 23 | 23 | 19 | 20 | 23 | 20 | 21 | 21 | 10 |
| Received at least 1 dose of study drug(s) | 12 | 12 | 6 | 13 | 6 | 23 | 23 | 19 | 20 | 23 | 20 | 21 | 21 | 10 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 12 | 12 | 6 | 13 | 6 | 23 | 23 | 19 | 20 | 23 | 20 | 21 | 21 | 10 |
| Withdrew: Progressive disease (radiographic) | 3 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease (clinical) | 7 | 8 | 3 | 9 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 |
| Withdrew: Participant moved into special access scheme | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 1 | 2 | 2 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 2 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 13 | 14 | 10 | 9 | 21 | 17 | 15 | 18 | 7 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Participants transferred to lte | 0 | 0 | 0 | 0 | 0 | 10 | 8 | 8 | 10 | 1 | 2 | 4 | 1 | 1 |
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. All AEs reported are treatment-emergent, which was defined as having a reported onset time or worsening in severity on or after the date of the first dose of study treatment through 30 days after the last dose (permanent discontinuation of study treatment) or initiation of new anticancer therapy. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
| Participants | Part A: Dose Escalation Phase - Cohort 1 | Part A: Dose Escalation Phase - Cohort 2 | Part A: Dose Escalation Phase - Cohort 3 | Part A: Dose Escalation Phase - Cohort 4 | Part A: Dose Escalation Phase - Cohort 5 |
|---|---|---|---|---|---|
| Part A: Number Of Participants Experiencing Adverse Events (AEs) | 12 | 12 | 6 | 13 | 6 |
DLT was defined as an AE or abnormal laboratory value assessed as unrelated to disease progression, intercurrent illness, or concomitant medications, and occurs during the first 21 days following the first dose of tislelizumab and pamiparib in Cycle 1 and meets protocol-specified criteria. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
| Participants | Part A: Dose Escalation Phase - Cohort 1 | Part A: Dose Escalation Phase - Cohort 2 | Part A: Dose Escalation Phase - Cohort 3 | Part A: Dose Escalation Phase - Cohort 4 | Part A: Dose Escalation Phase - Cohort 5 |
|---|---|---|---|---|---|
| Part A: Number Of Participants Experiencing Dose-limiting Toxicity (DLT) | 0 | 0 | 0 | 2 | 2 |
ORR was defined as the percentage of participants with a best overall response of complete response (CR) and partial response (PR).
| Participants | Part B: Dose Expansion Phase - Arm 1a | Part B: Dose Expansion Phase - Arm 1b | Part B: Dose Expansion Phase - Arm 2 | Part B: Dose Expansion Phase - Arm 3 | Part B: Dose Expansion Phase - Arm 4 | Part B: Dose Expansion Phase - Arm 5 | Part B: Dose Expansion Phase - Arm 6 | Part B: Dose Expansion Phase - Arm 7 | Part B: Dose Expansion Phase - Arm 8 |
|---|---|---|---|---|---|---|---|---|---|
| Part B: Objective Response Rate (ORR) | 7 | 3 | 9 | 4 | 2 | 2 | 6 | 0 | 3 |
PFS was defined as the time from first dose of study medication to the first documented objective disease progression or death due to any cause, whichever occurred first.
| month | Part B: Dose Expansion Phase - Arm 1a | Part B: Dose Expansion Phase - Arm 1b | Part B: Dose Expansion Phase - Arm 2 | Part B: Dose Expansion Phase - Arm 3 | Part B: Dose Expansion Phase - Arm 4 | Part B: Dose Expansion Phase - Arm 5 | Part B: Dose Expansion Phase - Arm 6 | Part B: Dose Expansion Phase - Arm 7 | Part B: Dose Expansion Phase - Arm 8 |
|---|---|---|---|---|---|---|---|---|---|
| Part B: Progression-free Survival (PFS) | 8.2 (5.2 to 11.8) | 3.5 (1.9 to 7.6) | 8.4 (3.9 to 19.0) | 10.4 (4.3 to 16.2) | 2.0 (1.7 to 2.3) | 2.1 (1.9 to 4.1) | 3.5 (1.9 to 7.5) | 1.9 (1.1 to 2.1) | 2.2 (1.2 to 24.4) |
DOR, defined as the time from the first determination of an objective response, was assessed by investigator per Response Evaluation Criteria in Solid Tumors v1.1 until the first documentation of progression or death, whichever occurred first. Results are reported only for arms with responders.
| months | Part B: Dose Expansion Phase - Arm 1a | Part B: Dose Expansion Phase - Arm 1b | Part B: Dose Expansion Phase - Arm 2 | Part B: Dose Expansion Phase - Arm 3 | Part B: Dose Expansion Phase - Arm 4 | Part B: Dose Expansion Phase - Arm 5 | Part B: Dose Expansion Phase - Arm 6 | Part B: Dose Expansion Phase - Arm 8 |
|---|---|---|---|---|---|---|---|---|
| Part B: Duration Of Response (DOR) | 11.2 (6.2 to NA) | 6.2 (3.8 to NA) | 17.1 (3.0 to NA) | NA (4.1 to NA) | 6.2 (4.3 to 8.1) | NA (NA to NA) | NA (5.7 to NA) | NA (22.4 to NA) |
DCR was defined as the percentage of participants with a best overall response of CR, PR, and stable disease (SD).
| Participants | Part B: Dose Expansion Phase - Arm 1a | Part B: Dose Expansion Phase - Arm 1b | Part B: Dose Expansion Phase - Arm 2 | Part B: Dose Expansion Phase - Arm 3 | Part B: Dose Expansion Phase - Arm 4 | Part B: Dose Expansion Phase - Arm 5 | Part B: Dose Expansion Phase - Arm 6 | Part B: Dose Expansion Phase - Arm 7 | Part B: Dose Expansion Phase - Arm 8 |
|---|---|---|---|---|---|---|---|---|---|
| Part B: Disease Control Rate (DCR) | 21 | 11 | 14 | 15 | 7 | 7 | 12 | 2 | 4 |
CBR was defined as the percentage of participants with a best overall response of CR, PR, and SD lasting ≥ 24 weeks.
| Participants | Part B: Dose Expansion Phase - Arm 1a | Part B: Dose Expansion Phase - Arm 1b | Part B: Dose Expansion Phase - Arm 2 | Part B: Dose Expansion Phase - Arm 3 | Part B: Dose Expansion Phase - Arm 4 | Part B: Dose Expansion Phase - Arm 5 | Part B: Dose Expansion Phase - Arm 6 | Part B: Dose Expansion Phase - Arm 7 | Part B: Dose Expansion Phase - Arm 8 |
|---|---|---|---|---|---|---|---|---|---|
| Part B: Clinical Benefit Rate (CBR) | 15 | 7 | 11 | 10 | 4 | 4 | 8 | 1 | 3 |
OS was defined as the time from the date of first dose of study drug to death due to any cause.
| month | Part B: Dose Expansion Phase - Arm 1a | Part B: Dose Expansion Phase - Arm 1b | Part B: Dose Expansion Phase - Arm 2 | Part B: Dose Expansion Phase - Arm 3 | Part B: Dose Expansion Phase - Arm 4 | Part B: Dose Expansion Phase - Arm 5 | Part B: Dose Expansion Phase - Arm 6 | Part B: Dose Expansion Phase - Arm 7 | Part B: Dose Expansion Phase - Arm 8 |
|---|---|---|---|---|---|---|---|---|---|
| Part B: Overall Survival (OS) | 20.9 (13.5 to NA) | 18.7 (6.1 to 27.0) | 15.8 (10.4 to NA) | 21.2 (10.5 to NA) | 6.9 (3.3 to 11.5) | 7.4 (3.3 to 13.4) | 8.4 (4.4 to 17.1) | 4.1 (2.9 to 5.0) | 4.1 (1.2 to 19.5) |
| nanogram/milliliter | Part A: Dose Escalation Phase - Cohort 1 | Part A: Dose Escalation Phase - Cohort 2 | Part A: Dose Escalation Phase - Cohort 3 | Part A: Dose Escalation Phase - Cohort 4 | Part A: Dose Escalation Phase - Cohort 5 |
|---|---|---|---|---|---|
| Cycle 4 Day 1 (Pre-dose) | 23530 ± 48.02 | 26040 ± 58.04 | 26160 ± 23.69 | 30330 ± 58.28 | 53700 ± 81.62 |
| Cycle 4 Day 1 (4 h) | 74260 ± 20.70 | 66250 ± 47.28 | 69020 ± 16.47 | 104300 ± 35.31 | 119600 ± 33.83 |
| nanogram/milliliter | Part A: Dose Escalation Phase - Cohort 1 | Part A: Dose Escalation Phase - Cohort 2 | Part A: Dose Escalation Phase - Cohort 3 | Part A: Dose Escalation Phase - Cohort 4 | Part A: Dose Escalation Phase - Cohort 5 |
|---|---|---|---|---|---|
| Cycle 2 Day 1 (Pre-dose) | 772.9 ± 164.6 | 1258 ± 62.13 | 1209 ± 42.18 | 1876 ± 60.41 | 2754 ± 48.69 |
| Cycle 2 Day 1 (7 h) | 824.8 ± 130.6 | 1469 ± 38.14 | 1717 ± 55.56 | 2070 ± 47.36 | 2969 ± 48.77 |
| nanogram/milliliter | Part A: Dose Escalation Phase - Cohort 1 | Part A: Dose Escalation Phase - Cohort 2 | Part A: Dose Escalation Phase - Cohort 3 | Part A: Dose Escalation Phase - Cohort 4 | Part A: Dose Escalation Phase - Cohort 5 |
|---|---|---|---|---|---|
| Part A: Maximum Observed Plasma Concentration At Steady State (Cmax,ss) Of Pamiparib | 1457 | 2497 | 2985 | 2586 | 3189 |
| hour | Part A: Dose Escalation Phase - Cohort 1 | Part A: Dose Escalation Phase - Cohort 2 | Part A: Dose Escalation Phase - Cohort 3 | Part A: Dose Escalation Phase - Cohort 4 | Part A: Dose Escalation Phase - Cohort 5 |
|---|---|---|---|---|---|
| Part A: Time To Reach Maximum Plasma Concentration At Steady State (Tmax,ss) Of Pamiparib | 1.0 (0.60 to 6.2) | 1.1 (0.42 to 4.0) | 1.0 (1.0 to 7.1) | 1.9 (0.45 to 7.0) | 2.0 (0.92 to 3.8) |
| nanogram/milliliter | Part A: Dose Escalation Phase - Cohort 1 | Part A: Dose Escalation Phase - Cohort 2 | Part A: Dose Escalation Phase - Cohort 3 | Part A: Dose Escalation Phase - Cohort 4 | Part A: Dose Escalation Phase - Cohort 5 |
|---|---|---|---|---|---|
| Part A: Ctrough At Steady State (Ctrough,ss) Of Pamiparib | 494 ± 130 | 1170 ± 66 | 1151 ± 97 | 2135 ± 39 | 2554 ± 2.5 |
ORR was defined as the percentage of participants with a best overall response of CR and PR.
| Participants | Part A: Dose Escalation Phase - Cohort 1 | Part A: Dose Escalation Phase - Cohort 2 | Part A: Dose Escalation Phase - Cohort 3 | Part A: Dose Escalation Phase - Cohort 4 | Part A: Dose Escalation Phase - Cohort 5 |
|---|---|---|---|---|---|
| Part A: ORR | 1 | 3 | 0 | 3 | 3 |
PFS was defined as the time from first dose of study medication to the first documented objective disease progression or death due to any cause, whichever occurred first.
| Days | Part A: Dose Escalation Phase - Cohort 1 | Part A: Dose Escalation Phase - Cohort 2 | Part A: Dose Escalation Phase - Cohort 3 | Part A: Dose Escalation Phase - Cohort 4 | Part A: Dose Escalation Phase - Cohort 5 |
|---|---|---|---|---|---|
| Part A: PFS | 64 (46 to 125) | 77 (42 to 568) | 190 (39 to 963) | 107 (58 to 249) | 373 (106 to 516) |
DCR was defined as the percentage of participants with a best overall response of CR, PR, and SD.
| Participants | Part A: Dose Escalation Phase - Cohort 1 | Part A: Dose Escalation Phase - Cohort 2 | Part A: Dose Escalation Phase - Cohort 3 | Part A: Dose Escalation Phase - Cohort 4 | Part A: Dose Escalation Phase - Cohort 5 |
|---|---|---|---|---|---|
| Part A: DCR | 3 | 6 | 5 | 7 | 5 |
CBR was defined as the percentage of participants with a best overall response of CR, PR, and SD lasting ≥ 24 weeks.
| week | Part A: Dose Escalation Phase - Cohort 1 | Part A: Dose Escalation Phase - Cohort 2 | Part A: Dose Escalation Phase - Cohort 3 | Part A: Dose Escalation Phase - Cohort 4 | Part A: Dose Escalation Phase - Cohort 5 |
|---|---|---|---|---|---|
| Part A: CBR | 2 ± 16.7 | 5 ± 41.7 | 4 ± 66.7 | 4 ± 30.8 | 4 ± 66.7 |
OS was defined as the time from the date of first dose of study drug to death due to any cause.
| Days | Part A: Dose Escalation Phase - Cohort 1 | Part A: Dose Escalation Phase - Cohort 2 | Part A: Dose Escalation Phase - Cohort 3 | Part A: Dose Escalation Phase - Cohort 4 | Part A: Dose Escalation Phase - Cohort 5 |
|---|---|---|---|---|---|
| Part A: OS | 259 (46 to 437) | 413 (54 to 1127) | NA (107 to NA) | 434 (128 to 577) | NA (178 to NA) |
Immunogenicity was summarized by participants who were ADA positive and developed detectable ADAs.
| Participants | Part A: Dose Escalation Phase - Cohort 1 | Part A: Dose Escalation Phase - Cohort 2 | Part A: Dose Escalation Phase - Cohort 3 | Part A: Dose Escalation Phase - Cohort 4 | Part A: Dose Escalation Phase - Cohort 5 |
|---|---|---|---|---|---|
| Part A: Percentage Of Participants With Anti-drug Antibodies (ADAs) For Tislelizumab | 3 | 1 | 0 | 1 | 0 |
An AE was defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study drug, whether considered related to study drug or not. All AEs reported are treatment-emergent, which was defined as having a reported onset time or worsening in severity on or after the date of the first dose of study treatment through 30 days after the last dose (permanent discontinuation of study treatment) or initiation of new anticancer therapy. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
| Participants | Part B: Dose Expansion Phase - Arm 1a | Part B: Dose Expansion Phase - Arm 1b | Part B: Dose Expansion Phase - Arm 2 | Part B: Dose Expansion Phase - Arm 3 | Part B: Dose Expansion Phase - Arm 4 | Part B: Dose Expansion Phase - Arm 5 | Part B: Dose Expansion Phase - Arm 6 | Part B: Dose Expansion Phase - Arm 7 | Part B: Dose Expansion Phase - Arm 8 |
|---|---|---|---|---|---|---|---|---|---|
| Part B: Number Of Participants Experiencing AEs | 23 | 23 | 19 | 20 | 23 | 20 | 21 | 21 | 9 |
As pre-specified in the protocol, pharmacokinetic evaluations were performed for all Part B dose expansion arms combined.
| nanogram/milliliter | Part B: Dose Expansion Phase |
|---|---|
| Part B: Ctrough Of Tislelizumab | 46060 ± 36 |
As pre-specified in the protocol, pharmacokinetic evaluations were performed for all Part B dose expansion arms combined.
| nanogram/milliliter | Part B: Dose Expansion Phase |
|---|---|
| Part B: Maximum Observed Plasma Concentration (Cmax) Of Tislelizumab | 99408 ± 20 |
As pre-specified in the protocol, pharmacokinetic evaluations were performed for all Part B dose expansion arms combined.
| nanogram/milliliter | Part B: Dose Expansion Phase |
|---|---|
| Part B: Ctrough Of Pamiparib | 1161 ± 80 |
As pre-specified in the protocol, pharmacokinetic evaluations were performed for all Part B dose expansion arms combined.
| nanogram/milliliter | Part B: Dose Expansion Phase |
|---|---|
| Part B: Cmax Of Pamiparib | 1850 ± 63 |
Immunogenicity was summarized by participants who developed detectable ADAs. Treatment-emergent ADAs: sum of both treatment-induced ADAs and treatment-boosted ADAs.
| Participants | Part B: Dose Expansion Phase - Arm 1a | Part B: Dose Expansion Phase - Arm 1b | Part B: Dose Expansion Phase - Arm 2 | Part B: Dose Expansion Phase - Arm 3 | Part B: Dose Expansion Phase - Arm 4 | Part B: Dose Expansion Phase - Arm 5 | Part B: Dose Expansion Phase - Arm 6 | Part B: Dose Expansion Phase - Arm 7 | Part B: Dose Expansion Phase - Arm 8 |
|---|---|---|---|---|---|---|---|---|---|
| Treatment-emergent ADA | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 2 |
| Treatment-boosted ADA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Treatment-induced ADA | 0 | 0 | 1 | 0 | 1 | 1 | 0 | 0 | 2 |
| Persistent ADA Response | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Transient ADA Response | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 2 |
| NAb Positive | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Day 1 through 4 years and 7 months. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Dose Escalation Phase - Cohort 1 | 11/12 (91.7%) | 5/12 (41.7%) | 12/12 (100%) |
| Part A: Dose Escalation Phase - Cohort 2 | 9/12 (75%) | 5/12 (41.7%) | 11/12 (91.7%) |
| Part A: Dose Escalation Phase - Cohort 3 | 2/6 (33.3%) | 3/6 (50%) | 5/6 (83.3%) |
| Part A: Dose Escalation Phase - Cohort 4 | 10/13 (76.9%) | 6/13 (46.2%) | 12/13 (92.3%) |
| Part A: Dose Escalation Phase - Cohort 5 | 3/6 (50%) | 5/6 (83.3%) | 6/6 (100%) |
| Part B: Dose Expansion Phase - Arm 1a | 13/23 (56.5%) | 6/23 (26.1%) | 21/23 (91.3%) |
| Part B: Dose Expansion Phase - Arm 1b | 14/23 (60.9%) | 16/23 (69.6%) | 22/23 (95.7%) |
| Part B: Dose Expansion Phase - Arm 2 | 10/19 (52.6%) | 7/19 (36.8%) | 16/19 (84.2%) |
| Part B: Dose Expansion Phase - Arm 3 | 9/20 (45%) | 8/20 (40%) | 13/20 (65%) |
| Part B: Dose Expansion Phase - Arm 4 | 21/23 (91.3%) | 14/23 (60.9%) | 15/23 (65.2%) |
| Part B: Dose Expansion Phase - Arm 5 | 17/20 (85%) | 10/20 (50%) | 17/20 (85%) |
| Part B: Dose Expansion Phase - Arm 6 | 15/21 (71.4%) | 13/21 (61.9%) | 14/21 (66.7%) |
| Part B: Dose Expansion Phase - Arm 7 | 20/21 (95.2%) | 8/21 (38.1%) | 18/21 (85.7%) |
| Part B: Dose Expansion Phase - Arm 8 | 8/10 (80%) | 8/10 (80%) | 5/10 (50%) |
| Event | Part A: Dose Escalation Phase - Cohort 1 | Part A: Dose Escalation Phase - Cohort 2 | Part A: Dose Escalation Phase - Cohort 3 | Part A: Dose Escalation Phase - Cohort 4 | Part A: Dose Escalation Phase - Cohort 5 | Part B: Dose Expansion Phase - Arm 1a | Part B: Dose Expansion Phase - Arm 1b | Part B: Dose Expansion Phase - Arm 2 | Part B: Dose Expansion Phase - Arm 3 | Part B: Dose Expansion Phase - Arm 4 | Part B: Dose Expansion Phase - Arm 5 | Part B: Dose Expansion Phase - Arm 6 | Part B: Dose Expansion Phase - Arm 7 | Part B: Dose Expansion Phase - Arm 8 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/12 | 0/12 | 0/6 | 0/13 | 0/6 | 0/23 | 0/23 | 0/19 | 0/20 | 0/23 | 1/20 | 0/21 | 1/21 | 2/10 |
| Small intestinal obstructionGastrointestinal disorders | 1/12 | 0/12 | 0/6 | 1/13 | 0/6 | 2/23 | 4/23 | 0/19 | 0/20 | 0/23 | 1/20 | 0/21 | 0/21 | 1/10 |
| VomitingGastrointestinal disorders | 0/12 | 0/12 | 0/6 | 2/13 | 1/6 | 0/23 | 1/23 | 0/19 | 0/20 | 0/23 | 1/20 | 0/21 | 0/21 | 1/10 |
| PyrexiaGeneral disorders | 0/12 | 1/12 | 1/6 | 0/13 | 1/6 | 0/23 | 0/23 | 1/19 | 1/20 | 1/23 | 0/20 | 2/21 | 0/21 | 0/10 |
| Autoimmune hepatitisHepatobiliary disorders | 1/12 | 0/12 | 0/6 | 0/13 | 1/6 | 1/23 | 0/23 | 0/19 | 0/20 | 1/23 | 0/20 | 0/21 | 0/21 | 0/10 |
| Immune-mediated hepatitisHepatobiliary disorders | 0/12 | 0/12 | 0/6 | 0/13 | 1/6 | 2/23 | 3/23 | 0/19 | 0/20 | 0/23 | 0/20 | 1/21 | 0/21 | 0/10 |
| Malignant biliary obstructionHepatobiliary disorders | 0/12 | 0/12 | 1/6 | 0/13 | 0/6 | 0/23 | 0/23 | 0/19 | 0/20 | 0/23 | 0/20 | 0/21 | 0/21 | 0/10 |
| Escherichia bacteraemiaInfections and infestations | 0/12 | 0/12 | 1/6 | 0/13 | 0/6 | 0/23 | 0/23 | 0/19 | 0/20 | 0/23 | 0/20 | 0/21 | 0/21 | 0/10 |
| Lower respiratory tract infection viralInfections and infestations | 0/12 | 0/12 | 1/6 | 0/13 | 0/6 | 0/23 | 0/23 | 0/19 | 0/20 | 0/23 | 0/20 | 0/21 | 0/21 | 0/10 |
| Pneumocystis jirovecii pneumoniaInfections and infestations | 0/12 | 0/12 | 1/6 | 0/13 | 0/6 | 0/23 | 0/23 | 0/19 | 0/20 | 0/23 | 0/20 | 0/21 | 0/21 | 0/10 |
| Event | Part A: Dose Escalation Phase - Cohort 1 | Part A: Dose Escalation Phase - Cohort 2 | Part A: Dose Escalation Phase - Cohort 3 | Part A: Dose Escalation Phase - Cohort 4 | Part A: Dose Escalation Phase - Cohort 5 | Part B: Dose Expansion Phase - Arm 1a | Part B: Dose Expansion Phase - Arm 1b | Part B: Dose Expansion Phase - Arm 2 | Part B: Dose Expansion Phase - Arm 3 | Part B: Dose Expansion Phase - Arm 4 | Part B: Dose Expansion Phase - Arm 5 | Part B: Dose Expansion Phase - Arm 6 | Part B: Dose Expansion Phase - Arm 7 | Part B: Dose Expansion Phase - Arm 8 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 5/12 | 10/12 | 4/6 | 10/13 | 5/6 | 18/23 | 17/23 | 15/19 | 8/20 | 8/23 | 7/20 | 12/21 | 12/21 | 3/10 |
| DiarrhoeaGastrointestinal disorders | 1/12 | 6/12 | 4/6 | 5/13 | 3/6 | 10/23 | 6/23 | 8/19 | 4/20 | 4/23 | 6/20 | 6/21 | 3/21 | 1/10 |
| FatigueGeneral disorders | 7/12 | 7/12 | 3/6 | 7/13 | 4/6 | 10/23 | 15/23 | 12/19 | 12/20 | 5/23 | 11/20 | 9/21 | 9/21 | 5/10 |
| VomitingGastrointestinal disorders | 1/12 | 7/12 | 1/6 | 5/13 | 3/6 | 6/23 | 5/23 | 8/19 | 3/20 | 2/23 | 4/20 | 4/21 | 3/21 | 2/10 |
| AnaemiaBlood and lymphatic system disorders | 2/12 | 2/12 | 2/6 | 4/13 | 3/6 | 5/23 | 2/23 | 10/19 | 5/20 | 3/23 | 2/20 | 5/21 | 5/21 | 2/10 |
| Back painMusculoskeletal and connective tissue disorders | 1/12 | 3/12 | 3/6 | 0/13 | 3/6 | 8/23 | 3/23 | 5/19 | 5/20 | 5/23 | 4/20 | 3/21 | 3/21 | 0/10 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/12 | 0/12 | 3/6 | 0/13 | 2/6 | 3/23 | 1/23 | 2/19 | 0/20 | 0/23 | 0/20 | 1/21 | 0/21 | 0/10 |
| Alanine aminotransferase increasedInvestigations | 1/12 | 2/12 | 3/6 | 3/13 | 3/6 | 4/23 | 3/23 | 3/19 | 3/20 | 2/23 | 2/20 | 8/21 | 1/21 | 2/10 |
| Aspartate aminotransferase increasedInvestigations | 1/12 | 2/12 | 3/6 | 3/13 | 1/6 | 3/23 | 3/23 | 3/19 | 3/20 | 2/23 | 2/20 | 9/21 | 2/21 | 2/10 |
| ConstipationGastrointestinal disorders | 4/12 | 3/12 | 1/6 | 1/13 | 1/6 | 4/23 | 8/23 | 5/19 | 6/20 | 3/23 | 8/20 | 3/21 | 5/21 | 0/10 |
Safety Analysis Set: all participants who received at least 1 dose of tislelizumab and/or pamiparib.
| Age, Continuous(years) | Part A: Dose Escalation Phase - Cohort 1 | Part A: Dose Escalation Phase - Cohort 2 | Part A: Dose Escalation Phase - Cohort 3 | Part A: Dose Escalation Phase - Cohort 4 | Part A: Dose Escalation Phase - Cohort 5 | Part B: Dose Expansion Phase - Arm 1a | Part B: Dose Expansion Phase - Arm 1b | Part B: Dose Expansion Phase - Arm 2 | Part B: Dose Expansion Phase - Arm 3 | Part B: Dose Expansion Phase - Arm 4 | Part B: Dose Expansion Phase - Arm 5 | Part B: Dose Expansion Phase - Arm 6 | Part B: Dose Expansion Phase - Arm 7 | Part B: Dose Expansion Phase - Arm 8 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 61.9 ± 9.39 | 58.6 ± 9.52 | 54.5 ± 11.27 | 61.8 ± 11.42 | 64.3 ± 5.96 | 59.5 ± 10.71 | 69.1 ± 8.68 | 50.4 ± 12.41 | 68.0 ± 8.89 | 64.2 ± 9.87 | 58.5 ± 13.71 | 68.9 ± 10.45 | 63.3 ± 9.11 | 60.1 ± 16.20 | 62.3 ± 11.7 |
| Sex: Female, Male(Participants) | Part A: Dose Escalation Phase - Cohort 1 | Part A: Dose Escalation Phase - Cohort 2 | Part A: Dose Escalation Phase - Cohort 3 | Part A: Dose Escalation Phase - Cohort 4 | Part A: Dose Escalation Phase - Cohort 5 | Part B: Dose Expansion Phase - Arm 1a | Part B: Dose Expansion Phase - Arm 1b | Part B: Dose Expansion Phase - Arm 2 | Part B: Dose Expansion Phase - Arm 3 | Part B: Dose Expansion Phase - Arm 4 | Part B: Dose Expansion Phase - Arm 5 | Part B: Dose Expansion Phase - Arm 6 | Part B: Dose Expansion Phase - Arm 7 | Part B: Dose Expansion Phase - Arm 8 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 9 | 11 | 5 | 12 | 5 | 23 | 23 | 19 | 0 | 10 | 3 | 6 | 9 | 5 | 140 |
| Male | 3 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 20 | 13 | 17 | 15 | 12 | 5 | 89 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Dose Escalation Phase - Cohort 1 | Part A: Dose Escalation Phase - Cohort 2 | Part A: Dose Escalation Phase - Cohort 3 | Part A: Dose Escalation Phase - Cohort 4 | Part A: Dose Escalation Phase - Cohort 5 | Part B: Dose Expansion Phase - Arm 1a | Part B: Dose Expansion Phase - Arm 1b | Part B: Dose Expansion Phase - Arm 2 | Part B: Dose Expansion Phase - Arm 3 | Part B: Dose Expansion Phase - Arm 4 | Part B: Dose Expansion Phase - Arm 5 | Part B: Dose Expansion Phase - Arm 6 | Part B: Dose Expansion Phase - Arm 7 | Part B: Dose Expansion Phase - Arm 8 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 0 | 1 | 1 | 0 | 0 | 7 |
| Not Hispanic or Latino | 12 | 12 | 6 | 13 | 6 | 22 | 22 | 16 | 18 | 21 | 17 | 17 | 19 | 9 | 210 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 3 | 2 | 1 | 12 |
| Race (NIH/OMB)(Participants) | Part A: Dose Escalation Phase - Cohort 1 | Part A: Dose Escalation Phase - Cohort 2 | Part A: Dose Escalation Phase - Cohort 3 | Part A: Dose Escalation Phase - Cohort 4 | Part A: Dose Escalation Phase - Cohort 5 | Part B: Dose Expansion Phase - Arm 1a | Part B: Dose Expansion Phase - Arm 1b | Part B: Dose Expansion Phase - Arm 2 | Part B: Dose Expansion Phase - Arm 3 | Part B: Dose Expansion Phase - Arm 4 | Part B: Dose Expansion Phase - Arm 5 | Part B: Dose Expansion Phase - Arm 6 | Part B: Dose Expansion Phase - Arm 7 | Part B: Dose Expansion Phase - Arm 8 | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 2 | 0 | 1 | 2 | 0 | 2 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 2 | 12 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 3 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 0 | 3 |
| White | 10 | 12 | 5 | 11 | 6 | 20 | 23 | 17 | 18 | 18 | 16 | 18 | 19 | 8 | 201 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 2 | 3 | 0 | 0 | 10 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Feb 2016 to primary completion in Sep 2020, 55 months.
Results were first posted in Dec 2021, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tislelizumab · Pamiparib